Heterogeneous HER2 Amplification—a New Clinical Category of HER2-Positive Breast Cancer?
Hossein Fallahi
December 21, 2022
HER2 amplification heterogeneity is associated with resistance to trastuzumab emtansine in the neoadjuvant setting, emphasizing the importance of assessing whether heterogeneous HER2-positive cancers require different treatment pathways. See related paper in Cancer Discovery.